scispace - formally typeset
Open AccessJournal ArticleDOI

Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia

Reads0
Chats0
TLDR
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.
Abstract
In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Деплеция в-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (covid-19)

TL;DR: According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Journal ArticleDOI

Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues

TL;DR: The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
Journal ArticleDOI

Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology

TL;DR: The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Journal ArticleDOI

Rheumatoid arthritis and post-COVID-19 syndrome

TL;DR: It is thought that SARS-CoV-2 infection may be a trigger factor for new rheumatic musculoskeletal diseases, including rheumatoid arthritis or COVID-19 can unmask previously undetected RA, and arthritis in the post covid period may induce problems in differential diagnosis of rhematic diseases.
Journal ArticleDOI

Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)

TL;DR: Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
References
More filters
Journal ArticleDOI

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.

TL;DR: In this article, a retrospective chart review of adult patients from one rheumatology practice who received at least one dose of a COVID-19 vaccine was performed, and the primary outcome was the presence of a serological response to vaccination.
Journal ArticleDOI

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Aeschlimann Florence, +392 more
TL;DR: In this paper, the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) was examined, and the most significant clinically relevant factors were analyzed by multivariable penalised logistic regression models, using a forward selection method.
Journal ArticleDOI

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A. Sparks, +66 more
TL;DR: In this article, the authors investigated baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).
Journal ArticleDOI

Rheumatic disease and COVID-19: epidemiology and outcomes.

TL;DR: Patients with rheumatoid arthritis, systemic lupus erythematosus or psoriasis, when analysed as a combined group, might have a slightly increased risk of death from COVID-19 compared to those without these diseases, although the role of disease activity and treatment in this risk estimation was not taken into account.
Related Papers (5)